Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC.
Tomoki Tamura
No relevant relationships to disclose
Katsuyuki Hotta
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Hiroko Gotoda
No relevant relationships to disclose
Yuka Kato
No relevant relationships to disclose
Eiki Ichihara
No relevant relationships to disclose
Toshio Kubo
No relevant relationships to disclose
Mitsune Tanimoto
No relevant relationships to disclose
Katsuyuki Kiura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma